Ultragenyx outlines 2027 profitability plan with R&D under $350M and SG&A under $375M following GTX-102 discontinuation

Ultragenyx Q3 2026: FDA approvals, pipeline cuts, cost resets, and 2027 profitability outlook.

CryptoAlerta — análise de criptomoedas e mercado em tempo real